Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development